{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:18:54Z","timestamp":1792736334969,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.amepre.2021.04.036","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:25:03Z","timestamp":1634689503000},"page":"S73-S86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"S1","title":["Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S."],"prefix":"10.1016","volume":"61","author":[{"given":"Lindsey E.","family":"Garrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Haberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.amepre.2021.04.036_bib0001","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"9883","key":"10.1016\/j.amepre.2021.04.036_bib0002","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.amepre.2021.04.036_bib0003","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amepre.2021.04.036_bib0004","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amepre.2021.04.036_bib0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/COH.0000000000000220","article-title":"Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice","volume":"11","author":"Haberer","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"10.1016\/j.amepre.2021.04.036_bib0007","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.amepre.2021.04.036_bib0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/QAI.0000000000001579","article-title":"Evolving models and ongoing challenges for HIV preexposure prophylaxis implementation in the United States","volume":"77","author":"Mayer","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.amepre.2021.04.036_bib0009","year":"2020"},{"issue":"12","key":"10.1016\/j.amepre.2021.04.036_bib0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annepidem.2018.06.009","article-title":"Trends in the use of oral emtricitabine\/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017","volume":"28","author":"Sullivan","year":"2018","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.amepre.2021.04.036_bib0011","series-title":"U.S. Public Health Service: pre-exposure prophylaxis for the prevention of HIV infection in the United States \u22122017 update: a clinical practice guideline","year":"2018"},{"issue":"9","key":"10.1016\/j.amepre.2021.04.036_bib0012","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"issue":"151","key":"10.1016\/j.amepre.2021.04.036_bib0013","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine","volume":"214","author":"Cottrell","year":"2016","journal-title":"J Infect Dis"},{"issue":"suppl 2","key":"10.1016\/j.amepre.2021.04.036_bib0015","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1097\/QAI.0000000000002169","article-title":"PrEP 1.0 and beyond: optimizing a biobehavioral intervention","volume":"82","author":"Mayer","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.amepre.2021.04.036_bib0016","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","article-title":"Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm","volume":"29","author":"Haberer","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.amepre.2021.04.036_bib0017","unstructured":"Compendium of Evidence-Based Interventions and Best Practices for HIV Prevention. https:\/\/www.cdc.gov\/hiv\/research\/interventionresearch\/compendium\/index.html. Updated August 11, 2021. Accessed April 7, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0018","unstructured":"Compendium of evidence-based interventions and best practices for HIV prevention. Life-steps for PrEP: evidence-informed for PrEP medication adherence\/persistence. Centers Disease Control and Prevention. https:\/\/www.cdc.gov\/hiv\/pdf\/research\/interventionresearch\/compendium\/prep\/cdc-hiv-LifeSteps-PrEP-EI-PrEP.pdf. Updated July 6, 2020. Accessed December 21, 2020."},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cbpra.2016.02.004","article-title":"Life-Steps\u201d for PrEP adherence: demonstration of a CBT-based intervention to increase adherence to preexposure prophylaxis (PrEP) medication among sexual-minority men at high risk for HIV acquisition","volume":"24","author":"Taylor","year":"2017","journal-title":"Cogn Behav Pract"},{"issue":"5","key":"10.1016\/j.amepre.2021.04.036_bib0020","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1007\/s10461-016-1606-4","article-title":"Optimizing pre-exposure antiretroviral prophylaxis adherence in men who have sex with men: results of a pilot randomized controlled trial of \u201cLife-Steps for PrEP","volume":"21","author":"Mayer","year":"2017","journal-title":"AIDS Behav"},{"key":"10.1016\/j.amepre.2021.04.036_bib0021","series-title":"Paper Presented at: Conference on Retroviruses and Opportunistic Infections","article-title":"Brief behavioral intervention increases PrEP drug levels in a real-world setting","author":"Golub","year":"2017"},{"issue":"7","key":"10.1016\/j.amepre.2021.04.036_bib0022","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s10461-018-2291-2","article-title":"Integrated Next Step Counseling (iNSC) for sexual health and PrEP use among young men who have sex with men: implementation and observations from ATN110\/113","volume":"23","author":"Amico","year":"2019","journal-title":"AIDS Behav"},{"issue":"5","key":"10.1016\/j.amepre.2021.04.036_bib0023","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/QAI.0000000000001538","article-title":"Plasma tenofovir levels to support adherence to TDF\/FTC preexposure prophylaxis for HIV prevention in MSM in Los Angeles, California","volume":"76","author":"Landovitz","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.amepre.2021.04.036_bib0024","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/cid\/ciy810","article-title":"Randomized controlled trial of a mobile health intervention to promote retention and adherence to preexposure prophylaxis among young people at risk for human immunodeficiency virus: the EPIC Study","volume":"68","author":"Liu","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amepre.2021.04.036_bib0025","unstructured":"Compendium of evidence-based interventions and best practices for HIV prevention. iText: evidence-informed for PrEP medication adherence\/persistence. Centers for Disease Control and Prevention.https:\/\/www.cdc.gov\/hiv\/pdf\/research\/interventionresearch\/compendium\/prep\/cdc-hiv-intervention-prep-ei-itext.pdf. Updated February 5, 2021. Accessed April 12, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab328","article-title":"Results from a PrEP demonstration project for at-risk cisgender women in the United States","author":"Blumenthal","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.amepre.2021.04.036_bib0027","doi-asserted-by":"crossref","first-page":"e18640","DOI":"10.2196\/18640","article-title":"A mobile gaming intervention for persons on pre-exposure prophylaxis: protocol for intervention development and randomized controlled trial","volume":"9","author":"Whiteley","year":"2020","journal-title":"JMIR Res Protoc"},{"issue":"6","key":"10.1016\/j.amepre.2021.04.036_bib0028","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1071\/SH18084","article-title":"Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care","volume":"15","author":"Tung","year":"2018","journal-title":"Sex Health"},{"issue":"10","key":"10.1016\/j.amepre.2021.04.036_bib0029","doi-asserted-by":"crossref","first-page":"ofz365","DOI":"10.1093\/ofid\/ofz365","article-title":"Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States","volume":"6","author":"Havens","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/apc.2019.0235","article-title":"A pharmacist-led, same-day, HIV pre-exposure prophylaxis initiation program to increase PrEP uptake and decrease time to PrEP initiation","volume":"34","author":"Khosropour","year":"2020","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"10.1016\/j.amepre.2021.04.036_bib0031","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/cid\/ciy640","article-title":"A PreP model incorporating clinical pharmacist encounters and antimicrobial stewardship program oversight may improve retention in care","volume":"68","author":"Gauthier","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.amepre.2021.04.036_bib0032","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1007\/s10461-021-03197-w","article-title":"Project SLIP: implementation of a PrEP screening and linkage intervention in primary care","volume":"25","author":"Storholm","year":"2021","journal-title":"AIDS Behav"},{"issue":"3","key":"10.1016\/j.amepre.2021.04.036_bib0033","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cid\/ciy529","article-title":"Developing and assessing the feasibility of a home-based preexposure prophylaxis monitoring and support program","volume":"68","author":"Siegler","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"10.1016\/j.amepre.2021.04.036_bib0034","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10461-019-02654-x","article-title":"PrEP implementation and persistence in a county health department setting in Atlanta, GA","volume":"23","author":"Rolle","year":"2019","journal-title":"AIDS Behav"},{"key":"10.1016\/j.amepre.2021.04.036_bib0035","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Effectiveness of PrEP navigation models in the thrive demonstration project","author":"Henny","year":"2020"},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0036","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.2196\/formative.8623","article-title":"A simple pre-exposure prophylaxis (PrEP) optimization intervention for health care providers prescribing PrEP: pilot study","volume":"2","author":"Saberi","year":"2018","journal-title":"JMIR Form Res"},{"issue":"5","key":"10.1016\/j.amepre.2021.04.036_bib0037","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QAI.0000000000002382","article-title":"Feasibility of short-term PrEP uptake for men who have sex with men with episodic periods of increased HIV risk","volume":"84","author":"Egan","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.amepre.2021.04.036_bib0038","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11904-019-00447-4","article-title":"Implementation strategies to increase PrEP uptake in the South","volume":"16","author":"Sullivan","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.amepre.2021.04.036_bib0039","unstructured":"Ready Set, PrEP expands access to HIV prevention medications. HIV.gov.https:\/\/www.hiv.gov\/federal-response\/ending-the-hiv-epidemic\/prep-program. Updated August 11, 2021. Accessed December 13, 2020."},{"key":"10.1016\/j.amepre.2021.04.036_bib0040","unstructured":"U.S. patient access: Gilead patient support programs. Gilead.https:\/\/www.gilead.com\/purpose\/medication-access\/us-patient-access#truvadaid. Updated August 11, 2021. Accessed April 12, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0041","unstructured":"Life steps for PrEP for youth (LSPY). Clinical Trials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03805451. Updated June 30, 2020. Accessed December 30, 2020."},{"key":"10.1016\/j.amepre.2021.04.036_bib0042","unstructured":"Optimizing PrEP uptake and adherence among MSWs using a 2-stage randomization design. NIH, RePORTER. https:\/\/reporter.nih.gov\/project-details\/9546848. Updated August 11, 2021. Accessed April 8, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0043","unstructured":"Optimizing PrEP uptake and adherence among male sex workers (MSW) using a 2-stage randomization design. ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03086057. Updated March 15, 2021. Accessed April 8, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0044","unstructured":"Developing and pilot testing an adaptive intervention to facilitate PrEP uptake and maximize adherence among at-risk transgender women. NIH, RePORTER. https:\/\/reporter.nih.gov\/project-details\/10082543. Updated August 11, 2021. Accessed April 8, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0045","unstructured":"Retention in PrEP for African American MSM in Mississippi. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03256435. Updated January 31, 2019. Accessed April 8, 2021."},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0046","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13722-019-0137-5","article-title":"Linking women experiencing incarceration to community-based HIV pre-exposure prophylaxis care: protocol of a pilot trial","volume":"14","author":"Ramsey","year":"2019","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.amepre.2021.04.036_bib0047","unstructured":"MHealth for PrEP adherence by young adult MSM, phase 2. ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04633200. Updated November 18, 2020. Accessed December 28, 2020."},{"key":"10.1016\/j.amepre.2021.04.036_bib0048","unstructured":"DOT diary mobile app for pre-exposure prophylaxis adherence in young men. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03771638?term=PrEP+adherence&draw=2&rank=63. Updated August 11, 2021. Accessed December 28, 2020."},{"key":"10.1016\/j.amepre.2021.04.036_bib0049","unstructured":"PrEP iT! Mobile app intervention (PrEP iT!). ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509076. Updated August 11, 2021. Accessed January 20, 2021."},{"issue":"12","key":"10.1016\/j.amepre.2021.04.036_bib0050","doi-asserted-by":"crossref","first-page":"e10448","DOI":"10.2196\/10448","article-title":"Testing the efficacy of a social networking gamification app to improve pre-exposure prophylaxis adherence (P3: prepared, Protected, emPowered): protocol for a randomized controlled trial","volume":"7","author":"LeGrand","year":"2018","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.amepre.2021.04.036_bib0051","unstructured":"LYNX: a novel mobile app to support linkage to HIV\/STI testing PrEP for young men who have sex with men. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03177512?term=NCT03177512&rank=1. Updated August 11, 2021. Accessed January 21, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0052","unstructured":"Mobile-based application \u201cMyChoices\u201d. ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03179319?term=NCT03179319&rank=1. Updated December 16, 2020. Accessed January 15, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0053","unstructured":"PrEP-3D: an integrated pharmacy digital diary and delivery strategy to increase PrEP use among MSM. NIH RePORT.https:\/\/reporter.nih.gov\/search\/RnUuTwM9g0SlSiY4erTu3w\/project-details\/9780975. Updated August 11, 2021. Accessed April 8, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0054","unstructured":"Unified approach to address PrEP cascade for BMSM. NIH RePORT.https:\/\/reporter.nih.gov\/project-details\/9949385. Updated August 11, 2021. Accessed April 8, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0055","unstructured":"Mobile messaging intervention to present new HIV prevention options for men who have sex with men. ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03666247. Updated January 6, 2020. Accessed April 13, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0056","unstructured":"Evaluating the acceptability and uptake of pre-exposure prophylaxis (PrEP) for adolescent women in the deep South. ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03897725?term=PrEP+adherence&draw=3. Updated November 13, 2020. Accessed December 28, 2020."},{"key":"10.1016\/j.amepre.2021.04.036_bib0057","unstructured":"Development and pilot testing of a PrEP communication intervention and integration into existing HIV testing services for female IV drug using clients of a needle exchange. NIH RePORT.https:\/\/reporter.nih.gov\/project-details\/9848524. Updated August 11, 2021. Accessed April 8, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0058","unstructured":"Integrating PrEP into family planning services at Title X clinics in the Southeastern U.S. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04097834?term=PrEP+adherence&draw=2&rank=64. Updated August 11, 2021. Accessed December 28, 2020."},{"key":"10.1016\/j.amepre.2021.04.036_bib0059","unstructured":"Electronic pre-exposure prophylaxis (PrEP) initiation and maintenance home care system (ePrEP). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03729570?term=NCT03729570&rank=1. Updated August 11, 2021. Accessed January 13, 2020."},{"issue":"5","key":"10.1016\/j.amepre.2021.04.036_bib0060","doi-asserted-by":"crossref","first-page":"e13647","DOI":"10.2196\/13647","article-title":"Acceptability and feasibility of self-collecting biological specimens for HIV, sexually transmitted infection, and adherence testing among high-risk populations (Project Caboodle!): protocol for an exploratory mixed-methods study","volume":"8","author":"Sharma","year":"2019","journal-title":"JMIR Res Protoc"},{"issue":"4","key":"10.1016\/j.amepre.2021.04.036_bib0061","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1077-7229(99)80052-2","article-title":"Life-steps: applying cognitive behavioral therapy to HIV medication adherence","volume":"6","author":"Safren","year":"1999","journal-title":"Cogn Behav Pract"},{"issue":"9","key":"10.1016\/j.amepre.2021.04.036_bib0062","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0063","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0000000000001179","article-title":"An HIV preexposure prophylaxis demonstration project and safety study for young MSM","volume":"74","author":"Hosek","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.amepre.2021.04.036_bib0064","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017604","article-title":"Do digital innovations for HIV and sexually transmitted infections work? Results from a systematic review (1996-2017)","volume":"7","author":"Daher","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.amepre.2021.04.036_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/apc.2019.0181","article-title":"A systematic review of mobile phone interventions (SMS\/IVR\/Calls) to improve adherence and retention to antiretroviral treatment in low-and middle-income countries","volume":"34","author":"Demena","year":"2020","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0066","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2352-3018(16)30206-5","article-title":"Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.amepre.2021.04.036_bib0067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204091","article-title":"Effectiveness of short message services and voice call interventions for antiretroviral therapy adherence and other outcomes: a systematic review and meta-analysis","volume":"13","author":"Amankwaa","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.amepre.2021.04.036_bib0068","unstructured":"Compendium of Evidence-Based Interventions and Best Practices for HIV Prevention. PrEPmate: evidence-based for retention. Care, Evidence-Based for PrEP Medication Adherence\/Persistence. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/hiv\/pdf\/research\/interventionresearch\/compendium\/prep\/cdc-hiv-PrEPmate-EBI-PrEP.pdf. Updated July 6, 2020. Accessed December 21, 2020."},{"key":"10.1016\/j.amepre.2021.04.036_bib0069","unstructured":"A multilevel gaming intervention for persons on PrEP. ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02611362. Updated January 12, 2021. Accessed April 8, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0070","unstructured":"P3 (Prepared, Protected, emPowered). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03320512?term=PrEP+adherence&draw=2&rank=20. Updated August 11, 2021. Accessed December 28, 2020."},{"issue":"9","key":"10.1016\/j.amepre.2021.04.036_bib0071","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s10461-014-0839-3","article-title":"HIV providers\u2019 perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study","volume":"18","author":"Krakower","year":"2014","journal-title":"AIDS Behav"},{"issue":"11","key":"10.1016\/j.amepre.2021.04.036_bib0072","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112425","article-title":"Access to healthcare, HIV\/STI testing, and preferred pre-exposure prophylaxis providers among men who have sex with men and men who engage in street-based sex work in the U.S","volume":"9","author":"Underhill","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.amepre.2021.04.036_bib0073","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/apc.2018.0166","article-title":"Considering stigma in the provision of HIV pre-exposure prophylaxis: reflections from current prescribers","volume":"33","author":"Calabrese","year":"2019","journal-title":"AIDS Patient Care STDS"},{"issue":"12","key":"10.1016\/j.amepre.2021.04.036_bib0074","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2105\/AJPH.2017.304061","article-title":"Integrating HIV preexposure prophylaxis (PrEP) into routine preventive health care to avoid exacerbating disparities","volume":"107","author":"Calabrese","year":"2017","journal-title":"Am J Public Health"},{"key":"10.1016\/j.amepre.2021.04.036_bib0075","unstructured":"Welcome to magnet. San Francisco AIDS Foundation.https:\/\/www.sfaf.org\/programs\/magnet\/. Updated August 11, 2021. Accessed April 12, 2021."},{"issue":"1","key":"10.1016\/j.amepre.2021.04.036_bib0076","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.amepre.2021.04.036_bib0077","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s11904-020-00533-y","article-title":"Understanding, contextualizing, and addressing PrEP stigma to enhance PrEP implementation","volume":"17","author":"Calabrese","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.amepre.2021.04.036_bib0078","unstructured":"Pre-exposure prophylaxis (PrEP) at home (PrEP@Home). ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03569813. Updated August 11, 2021. Accessed April 13, 2021."},{"key":"10.1016\/j.amepre.2021.04.036_bib0079","series-title":"Mail order now an option for Ready, set, PrEP","year":"2021"},{"issue":"7","key":"10.1016\/j.amepre.2021.04.036_bib0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040734","article-title":"Improving the HIV PrEP continuum of care using an intervention for healthcare providers: a stepped-wedge study protocol","volume":"10","author":"Ming","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.amepre.2021.04.036_bib0081","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10508-019-01612-x","article-title":"Perceived confidentiality risks of mobile technology-based ecologic momentary assessment to assess high-risk behaviors among rural men who have sex with men","volume":"50","author":"Hubach","year":"2021","journal-title":"Arch Sex Behav"},{"key":"10.1016\/j.amepre.2021.04.036_bib0082","unstructured":"Overcoming PrEP across challenges with new nursing protocols. Centers for Disease Control and Prevention.https:\/\/www.cdc.gov\/endhiv\/action\/stories\/dekalb-county-nursing.html. Updated October 16, 2020. Accessed February 19, 2021."},{"issue":"10","key":"10.1016\/j.amepre.2021.04.036_bib0083","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/0956462419855178","article-title":"Pre-exposure prophylaxis access in federally qualified health centers across 11 United States metropolitan statistical areas","volume":"30","author":"Tookes","year":"2019","journal-title":"Int J STD AIDS"},{"issue":"3","key":"10.1016\/j.amepre.2021.04.036_bib0084","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/QAI.0000000000001914","article-title":"Vulnerable periods: characterizing patterns of sexual risk and substance use during lapses in adherence to HIV pre-exposure prophylaxis among men who have sex with men","volume":"80","author":"Wray","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 5","key":"10.1016\/j.amepre.2021.04.036_bib0085","doi-asserted-by":"crossref","first-page":"e25564","DOI":"10.1002\/jia2.25564","article-title":"Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial","volume":"23 Suppl 5","author":"Songtaweesin","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.amepre.2021.04.036_bib0086","series-title":"Qualitative accounts of PrEP discontinuation from the general population in Eswatini. Cult Health Sex","author":"B\u00e4rnighausen","year":"2020"},{"issue":"12","key":"10.1016\/j.amepre.2021.04.036_bib0087","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1080\/09540121.2020.1757021","article-title":"Assessing determinants of pre-exposure prophylaxis (PrEP) adherence among a sample of rural Midwestern men who have sex with men (MSM)","volume":"32","author":"Owens","year":"2020","journal-title":"AIDS Care"},{"issue":"10","key":"10.1016\/j.amepre.2021.04.036_bib0088","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1007\/s10461-020-02843-z","article-title":"HIV-related mistrust (or HIV conspiracy theories) and willingness to use PrEP among Black women in the United States","volume":"24","author":"Ojikutu","year":"2020","journal-title":"AIDS Behav"},{"issue":"11","key":"10.1016\/j.amepre.2021.04.036_bib0089","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/09540121.2017.1300633","article-title":"Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts","volume":"29","author":"Cahill","year":"2017","journal-title":"AIDS Care"},{"issue":"4","key":"10.1016\/j.amepre.2021.04.036_bib0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11904-019-00450-9","article-title":"Current and future PrEP medications and modalities: on-demand, injectables, and topicals","volume":"16","author":"Beymer","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"10.1016\/j.amepre.2021.04.036_bib0091","doi-asserted-by":"crossref","first-page":"203","DOI":"10.9745\/GHSP-D-13-00010","article-title":"Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009","volume":"1","author":"Ross","year":"2013","journal-title":"Glob Health Sci Pract"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379721003585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379721003585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:01:32Z","timestamp":1760083292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379721003585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0749379721003585"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2021.04.036","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S.","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2021.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Journal of Preventive Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}